NCT00923806 2026-01-23
Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
Clinical Trials
24 trialsNCT05035407 2025-12-02
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT01218867 2019-12-10
CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01369875 2019-12-10
Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00670748 2019-11-19
Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01583686 2019-10-14
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT02153905 2019-06-17
T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00923390 2019-04-09
Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT00001827 2017-10-06
p53 Vaccine for Ovarian Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02111863 2017-09-19
Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00089778 2017-08-01
Vaccine Treatment of Kidney Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01271907 2017-08-01
Drosophila-generated CTL
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT02062359 2016-06-24
T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00610311 2015-10-28
Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00704938 2015-10-28
Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or Recurrent Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00706992 2015-10-28
Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00924287 2015-10-28
Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01273181 2015-10-28
MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT01495572 2015-10-15
Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00303836 2013-06-06
Vaccine Therapy With or Without Interleukin-2 After Chemotherapy and an Autologous White Blood Cell Infusion in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00054405 2013-04-09
Interleukin-12 and Interleukin-2 in Treating Patients With Refractory or Recurrent Neuroblastoma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00052377 2013-01-16
Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides
National Cancer Institute (NCI)
Phase 1/2 Terminated
NCT00509496 2013-01-15
Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00924001 2012-10-25
Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated